Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Evinacumab in HoFH
NCT03409744Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of evinacumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events up to 216 weeks. Started Mar 2018; status: completed.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT03409744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409744.